CD4 and multiple sclerosis: Daclizumab (targeting IL-2Ralpha chain) therapy may relieve the symptoms of multiple sclerosis patients, which is associated with expansion of CD56bright NK cells and a gradual decline in circulating CD4+ T cells [34].